Gilead Sciences (GILD) Stock Price, News & Analysis

Company Overview

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company headquartered in Foster City, California, that focuses on the discovery, development and commercialization of innovative medicines. Since its founding in 1987 by Dr. Michael L. Riordan, Gilead has built a global presence with operations in North America, Europe, Asia and emerging markets. The company employs a research-driven model, investing heavily in clinical development and regulatory approvals to address unmet medical needs in viral and oncology therapeutics.

Gilead’s core business activities center on antiviral therapies, particularly for HIV and hepatitis C. Flagship products include Biktarvy and Descovy for HIV prevention and treatment, and Sovaldi and Harvoni for hepatitis C. In response to the COVID-19 pandemic, Gilead secured emergency use authorization for Veklury (remdesivir), an antiviral treatment that has been administered globally. Beyond antivirals, the company is expanding into oncology and inflammatory diseases, with cell therapy products such as Yescarta and Tecartus, which leverage CAR T technology to target specific cancers.

Over the years, Gilead has pursued strategic acquisitions and partnerships to bolster its pipeline. Notable transactions include the acquisition of Pharmasset in 2011, which fueled its hepatitis C franchise, and the purchase of Kite Pharma in 2017, establishing a foothold in cell therapy. The company supports a broad R&D network with centers in the U.S., Europe and Asia, collaborating with academic institutions, biotech firms and global health organizations to accelerate innovation.

Leadership at Gilead is guided by CEO Daniel O’Day, who joined the company in 2019 and brings experience from global healthcare organizations. Under his direction, Gilead has emphasized scientific rigor, operational efficiency and patient access initiatives. The company’s diverse executive team and board of directors maintain a strategic focus on sustainable growth, ethical conduct and advancing therapies that improve patient outcomes worldwide.

Key Stats

• Today's Range: $108.04 to $110.90
• 50-Day Range: $96.86 to $114.54
• 52-Week Range: $70.78 to $119.96
• Volume: 6.63 million shs
• Average Volume: 7.66 million shs
• Market Capitalization: $134.62 billion
• P/E Ratio: 14.06
• Dividend Yield: 2.92%
• Price Target: $111.38
• Consensus Rating: Moderate Buy

Gilead Sciences Stock Analysis - MarketRank™

Gilead Sciences scored higher than 98% of companies evaluated by MarketBeat, and ranked 34th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Gilead Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 14 buy ratings, 9 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Gilead Sciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 2.01%

Earnings Growth

Earnings for Gilead Sciences are expected to grow by 2.01% in the coming year, from $7.95 to $8.11 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Gilead Sciences is 22.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.51.

Price to Earnings Ratio vs. Sector

The P/E ratio of Gilead Sciences is 22.78, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.06.

Price to Earnings Growth Ratio

Gilead Sciences has a PEG Ratio of 0.71. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Gilead Sciences has a P/B Ratio of 7.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.69% of the float of Gilead Sciences has been sold short.

Short Interest Ratio / Days to Cover

Gilead Sciences has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Gilead Sciences has recently decreased by 8.70%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Gilead Sciences pays a meaningful dividend of 2.88%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Gilead Sciences has been increasing its dividend for 10 years.

Dividend Coverage

The dividend payout ratio of Gilead Sciences is 66.53%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 38.96% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -2.24

Percentage of Shares Shorted

1.69% of the float of Gilead Sciences has been sold short.

Short Interest Ratio / Days to Cover

Gilead Sciences has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Gilead Sciences has recently decreased by 8.70%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.85

News Sentiment

Gilead Sciences has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 70 news articles for Gilead Sciences this week, compared to 35 articles on an average week.

Search Interest

91 people have searched for GILD on MarketBeat in the last 30 days. This is an increase of 69% compared to the previous 30 days.

MarketBeat Follows

21 people have added Gilead Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Gilead Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,844,775.00 in company stock.

Percentage Held by Insiders

Only 0.27% of the stock of Gilead Sciences is held by insiders.

Percentage Held by Institutions

83.67% of the stock of Gilead Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GILD Stock Analysis - Frequently Asked Questions

How have GILD shares performed this year?

Gilead Sciences' stock was trading at $92.37 at the beginning of 2025. Since then, GILD shares have increased by 17.2% and is now trading at $108.22.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings data on Thursday, April, 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company's revenue for the quarter was down .3% compared to the same quarter last year.
Read the conference call transcript.

Does Gilead Sciences have any subsidiaries?

Gilead Sciences subsidiaries include these companies: MYR, Immunomedics, Forty Seven, Cell Design Labs, Kite Pharma, Nimbus Apollo, Epitherapeutics, and others.

Who are Gilead Sciences' major shareholders?

Gilead Sciences' top institutional investors include Robeco Institutional Asset Management B.V. (0.30%), Swedbank AB (0.19%), Kingstone Capital Partners Texas LLC (0.17%) and Assenagon Asset Management S.A. (0.11%). Insiders that own company stock include Daniel Patrick O'day, Andrew D Dickinson, Johanna Mercier, Merdad Parsey, Diane E Wilfong and Jeffrey Bluestone.
View institutional ownership trends.

How do I buy shares of Gilead Sciences?

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gilead Sciences investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Corning (GLW), NextEra Energy (NEE) and American Tower (AMT).

Company Calendar

• Last Earnings: 4/24/2025
• Record date for 6/27 Dividend: 6/13/2025
• Ex-Dividend for 6/27 Dividend: 6/13/2025
• Dividend Payable: 6/27/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GILD
• CIK: 882095
• Web: www.gilead.com
• Phone: (650) 574-3000
• Fax: 650-578-9264
• Employees: 17,600
• Year Founded: 1987

Price Target and Rating

• Average Price Target for Gilead Sciences: $111.38
• High Price Target: $140.00
• Low Price Target: $90.00
• Potential Upside/Downside: +2.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.77
• Research Coverage: 26 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.75
• Trailing P/E Ratio: 22.81
• Forward P/E Ratio: 13.61
• P/E Growth: 0.71
• Net Income: $480 million
• Net Margins: 20.76%
• Pretax Margin: 23.75%
• Return on Equity: 51.93%
• Return on Assets: 17.40%

Debt

• Debt-to-Equity Ratio: 1.16
• Current Ratio: 1.37
• Quick Ratio: 1.23

Sales & Book Value

• Annual Sales: $28.75 billion
• Price / Sales: 4.68
• Cash Flow: $6.77 per share
• Price / Cash Flow: 15.99
• Book Value: $15.44 per share
• Price / Book: 7.01

Miscellaneous

• Outstanding Shares: 1,243,930,000
• Free Float: 1,240,570,000
• Market Cap: $134.63 billion
• Optionable: Optionable
• Beta: 0.29